Udit Batra, Ph.D. is Chief Executive Officer of MilliporeSigma and a member of the Executive Board of Merck KGaA, Darmstadt, Germany. The $7.6 billion Life Science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Batra oversees the company’s Bioethics Advisory Panel and has Board responsibility for the global Information Technology function.

Born in New Delhi, India, Batra is an accomplished executive who has dedicated his career to improving health for people globally, bringing more than 20 years’ experience in healthcare and life science. After Batra became CEO of what was then EMD Millipore in 2014, he and his team developed and executed a growth strategy that included the 2015 acquisition of chemicals and technology giant Sigma-Aldrich. This merger created MilliporeSigma and marked the largest acquisition in the history of Merck KGaA, Darmstadt, Germany and one of the largest ever in the life science industry.

Batra has earned a reputation for driving business growth and turnarounds as well as building high-performing teams. Prior to his role as MilliporeSigma CEO, he was head of the global Consumer Health business of Merck KGaA, Darmstadt, Germany, where he and his team more than doubled the profitability of the business, making it the fastest-growing sector within the company at that time.

Earlier in his career, Batra served in a range of leadership positions at Novartis. Previous to this, Batra held senior positions in the healthcare, consumer and non-profit practices at McKinsey & Company. He began his career as a research engineer fellow at Merck & Co., Inc., where he worked on vaccines and small molecules. He earned both a Ph.D. and a B.S. in chemical engineering from Princeton University and the University of Delaware, respectively.

Batra serves as the chairman of the Massachusetts High Technology Council and as a board member on the Boston Chamber of Commerce and MassBio. He is also a member of the Advisory Council at Princeton University’s Department of Chemical Engineering and a member of the Advisory Council at the University of Delaware’s Department of Chemical Engineering.

An avid supporter of scientific education, Batra oversees MilliporeSigma’s key programs to spark scientific curiosity amongst school-aged children.
Kate Walsh is president and CEO of the Boston Medical Center (BMC) health system, with annual operating revenue of $4.9 billion. BMC is a private, not-for-profit, 514 bed, academic medical center with a community-based focus. The primary teaching affiliate of Boston University School of Medicine, Boston Medical Center has nearly 6000 employees and 755 physicians who are affiliated with Boston University Medical Group. BMC health system also includes the BMC HealthNet Plan, a Medicaid Managed Care Organization with nearly 400,000 members in Massachusetts and New Hampshire, and Boston HealthNet, a network affiliation of 14 community health centers throughout Boston.

Prior to her appointment at Boston Medical Center, Ms. Walsh served as executive vice president and chief operating officer of Brigham and Women’s Hospital. She served previously as the chief operating officer for Novartis Institutes for Biomedical Research and at Massachusetts General Hospital in positions including senior vice president of medical services and the MGH Cancer Center. Prior to her tenure at Mass General, she held positions in a number of New York City hospitals including Montefiore, Columbia Presbyterian Medical Center, Saint Luke’s – Roosevelt Hospital Center and the New York City Health and Hospitals Corporation.

Ms. Walsh received her bachelor of arts degree and a master’s degree in public health from Yale University. She is a member of the Boards of the Federal Reserve Bank of Boston, the Boston Public Health Commission, the Association of American Medical Colleges, Pine Street Inn, and Yale University.

Gianni Giacomelli serves as Chief Innovation Leader at Genpact.

In this role, Gianni drives and sponsors Genpact’s strategic initiatives aimed at sustaining clients’ transformation as digitally enabled companies. These initiatives include design-driven digital transformation initiatives and methods that take into account the human and organizational side of technological change.

Gianni also plays a leading innovation role in Genpact’s initiative with the Massachusetts Institute of Technology (MIT) to establish a Collective Intelligence Design Lab aimed at exploring and designing combined people-machine groups that are able to generate radical innovation.

He is widely published and quoted and is a frequent speaker at trade conferences. Gianni has authored several scientific papers in collaboration with MIT researchers and is an active blogger on digital and workplace topics.

In addition to leading many of Genpact’s portfolio extensions leveraging technology and analytics, Gianni chaired and launched Genpact’s Research Institute and was one of the main architects of the revolutionary Lean Digital approach intended to harness the power of digital technology in business operations. Gianni joined Genpact in 2010 to lead New Product Innovation and also served as Chief Marketing Officer for three years.
His career spans more than 24 years across innovation strategy, marketing, and transformation consulting with global and emerging leaders in professional services (such as Boston Consulting Group, Everest and Datamonitor) and software (SAP). He started his career in marketing analytics with the Danone Group.

Gianni holds a post-graduate degree in organizational and social behavior from the London School of Economics and a business administration degree from the EME Strasbourg Business School and the University of Florence. He has completed advanced education programs on innovation at Harvard University and at the Massachusetts Institute of Technology.

Gianni has lived in seven countries across Europe, North America and Asia.

David Sun Kong, Ph.D. is a Synthetic Biologist, community organizer, musician, and photographer based in Lexington, MA. He is the Director of the MIT Media Lab’s Community Bio Initiative, a pioneer in developing microfluidic, or “lab-on-a-chip” technologies for synthetic biology, and a leader in the global Community Bio movement.

In 2017, he founded the Global Community Bio Summit, a gathering convening the global network of community biology labs, and was recognized as an emerging leader in synthetic biology as a “LEAP” Fellow. He is co-founder of ‘How To Grow (Almost) Anything,’ an international course on synthetic biology taught with Professor George Church of Harvard, and founder of ‘Metafluidics,’ an open repository for fluidic systems.

David conducted his graduate studies at MIT’s Media Lab, receiving a master’s degree for developing technology for printing nanostructures with energetic beams and a Ph.D. for demonstrating the first gene synthesis in a microfluidic system. His research has been covered via outlets such as the Washington Post, Science, the Boston Globe, Gizmodo, and STAT News.

He has also performed as a DJ, beat-boxer, vocalist, and rapper at hundreds of venues, and his photography has been exhibited at the National Museum of American History at the Smithsonian and other museums and galleries across the country.

Patrick Schneider, Ph.D. is Head of Strategy, Business Development and Innovation for the Research Solutions Business Unit, and Chair of the Life Science Innovation Board as well as Chair of the Connected Lab and Gene Editing and Novel Modalities Promise Ventures at MilliporeSigma. His teams develop a wide range of research reagents, specialty chemicals, analytical instruments and kits for protein detection and biomarker discovery, as well as disposable devices and kits for sample preparation and processing, while also helping the Business Unit develop its strategy.
As Chairman of the Innovation Board and Promise Ventures, he leads the review of important scientific trends, oversees the performance of innovation across Life Science, and ensures cross-business collaboration.

Over 20 years of leadership experience with MilliporeSigma, he has held various leadership roles in R&D, business development, management of research reagents portfolio and new business initiatives. Prior to MilliporeSigma, Patrick was the Vice President of R&D and Business Development for Research Reagents at Serologicals. Past appointments include Chief Scientific Officer at Chemicon International and Vice President of Genome Biosciences.